cloudfront

Report Detail



OtherGlobal Oral Antidiabetic (OAD) Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • RnM2414343
  • |
  • 14 September, 2018
  • |
  • Global
  • |
  • 121 pages
  • |
  • GIR (Global Info Research)
  • |
  • Other

Global Oral Antidiabetic (OAD) Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Table of Contents

    1 Oral Antidiabetic (OAD) Treatment Market Overview

    • 1.1 Product Overview and Scope of Oral Antidiabetic (OAD) Treatment
    • 1.2 Classification of Oral Antidiabetic (OAD) Treatment by Types
    • 1.2.1 Global Oral Antidiabetic (OAD) Treatment Revenue Comparison by Types (2017-2023)
  • 1.2.2 Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Types in 2017
  • 1.2.3 Sulphonylureas
  • 1.2.4 Biguanides
  • 1.2.5 Intestinal α-Glucosidase Inhibitors
  • 1.2.6 Others
  • 1.3 Global Oral Antidiabetic (OAD) Treatment Market by Application
  • 1.3.1 Global Oral Antidiabetic (OAD) Treatment Market Size and Market Share Comparison by Applications (2013-2023)
  • 1.3.2 Hospital
  • 1.3.3 Clinics
  • 1.3.4 Diabetics Treatment Centres
  • 1.3.5 Others
  • 1.4 Global Oral Antidiabetic (OAD) Treatment Market by Regions
  • 1.4.1 Global Oral Antidiabetic (OAD) Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
  • 1.4.1 North America (USA, Canada and Mexico) Oral Antidiabetic (OAD) Treatment Status and Prospect (2013-2023)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Oral Antidiabetic (OAD) Treatment Status and Prospect (2013-2023)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Oral Antidiabetic (OAD) Treatment Status and Prospect (2013-2023)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Oral Antidiabetic (OAD) Treatment Status and Prospect (2013-2023)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Oral Antidiabetic (OAD) Treatment Status and Prospect (2013-2023)
  • 1.5 Global Market Size of Oral Antidiabetic (OAD) Treatment (2013-2023)
  • 2 Manufacturers Profiles

    • 2.1 Pfizer
    • 2.1.1 Business Overview
  • 2.1.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.1.2.1 Product A
  • 2.1.2.2 Product B
  • 2.1.3 Pfizer Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.2 Eli Lilly
  • 2.2.1 Business Overview
  • 2.2.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.2.2.1 Product A
  • 2.2.2.2 Product B
  • 2.2.3 Eli Lilly Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.3 Merck
  • 2.3.1 Business Overview
  • 2.3.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.3.2.1 Product A
  • 2.3.2.2 Product B
  • 2.3.3 Merck Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.4 Sanofi
  • 2.4.1 Business Overview
  • 2.4.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.4.2.1 Product A
  • 2.4.2.2 Product B
  • 2.4.3 Sanofi Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.5 AstraZeneca
  • 2.5.1 Business Overview
  • 2.5.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.5.2.1 Product A
  • 2.5.2.2 Product B
  • 2.5.3 AstraZeneca Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.6 Glenmark
  • 2.6.1 Business Overview
  • 2.6.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.6.2.1 Product A
  • 2.6.2.2 Product B
  • 2.6.3 Glenmark Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.7 Novartis
  • 2.7.1 Business Overview
  • 2.7.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.7.2.1 Product A
  • 2.7.2.2 Product B
  • 2.7.3 Novartis Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.8 Boehringer Ingelheim
  • 2.8.1 Business Overview
  • 2.8.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.8.2.1 Product A
  • 2.8.2.2 Product B
  • 2.8.3 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.9 Novo Nordisk
  • 2.9.1 Business Overview
  • 2.9.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.9.2.1 Product A
  • 2.9.2.2 Product B
  • 2.9.3 Novo Nordisk Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 2.10 Mannkind
  • 2.10.1 Business Overview
  • 2.10.2 Oral Antidiabetic (OAD) Treatment Type and Applications
  • 2.10.2.1 Product A
  • 2.10.2.2 Product B
  • 2.10.3 Mannkind Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
  • 3 Global Oral Antidiabetic (OAD) Treatment Market Competition, by Players

    • 3.1 Global Oral Antidiabetic (OAD) Treatment Revenue and Share by Players (2013-2018)
    • 3.2 Market Concentration Rate
    • 3.2.1 Top 5 Oral Antidiabetic (OAD) Treatment Players Market Share
  • 3.2.2 Top 10 Oral Antidiabetic (OAD) Treatment Players Market Share
  • 3.3 Market Competition Trend
  • 4 Global Oral Antidiabetic (OAD) Treatment Market Size by Regions

    • 4.1 Global Oral Antidiabetic (OAD) Treatment Revenue and Market Share by Regions
    • 4.2 North America Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 4.3 Europe Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 4.4 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 4.5 South America Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 4.6 Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)

    5 North America Oral Antidiabetic (OAD) Treatment Revenue by Countries

    • 5.1 North America Oral Antidiabetic (OAD) Treatment Revenue by Countries (2013-2018)
    • 5.2 USA Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 5.3 Canada Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 5.4 Mexico Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)

    6 Europe Oral Antidiabetic (OAD) Treatment Revenue by Countries

    • 6.1 Europe Oral Antidiabetic (OAD) Treatment Revenue by Countries (2013-2018)
    • 6.2 Germany Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 6.3 UK Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 6.4 France Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 6.5 Russia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 6.6 Italy Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)

    7 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue by Countries

    • 7.1 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue by Countries (2013-2018)
    • 7.2 China Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 7.3 Japan Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 7.4 Korea Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 7.5 India Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 7.6 Southeast Asia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)

    8 South America Oral Antidiabetic (OAD) Treatment Revenue by Countries

    • 8.1 South America Oral Antidiabetic (OAD) Treatment Revenue by Countries (2013-2018)
    • 8.2 Brazil Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 8.3 Argentina Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 8.4 Colombia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)

    9 Middle East and Africa Revenue Oral Antidiabetic (OAD) Treatment by Countries

    • 9.1 Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue by Countries (2013-2018)
    • 9.2 Saudi Arabia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 9.3 UAE Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 9.4 Egypt Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 9.5 Nigeria Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)
    • 9.6 South Africa Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2013-2018)

    10 Global Oral Antidiabetic (OAD) Treatment Market Segment by Type

    • 10.1 Global Oral Antidiabetic (OAD) Treatment Revenue and Market Share by Type (2013-2018)
    • 10.2 Global Oral Antidiabetic (OAD) Treatment Market Forecast by Type (2018-2023)
    • 10.3 Sulphonylureas Revenue Growth Rate (2013-2023)
    • 10.4 Biguanides Revenue Growth Rate (2013-2023)
    • 10.5 Intestinal α-Glucosidase Inhibitors Revenue Growth Rate (2013-2023)
    • 10.6 Others Revenue Growth Rate (2013-2023)

    11 Global Oral Antidiabetic (OAD) Treatment Market Segment by Application

    • 11.1 Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Application (2013-2018)
    • 11.2 Oral Antidiabetic (OAD) Treatment Market Forecast by Application (2018-2023)
    • 11.3 Hospital Revenue Growth (2013-2018)
    • 11.4 Clinics Revenue Growth (2013-2018)
    • 11.5 Diabetics Treatment Centres Revenue Growth (2013-2018)
    • 11.6 Others Revenue Growth (2013-2018)

    12 Global Oral Antidiabetic (OAD) Treatment Market Size Forecast (2018-2023)

    • 12.1 Global Oral Antidiabetic (OAD) Treatment Market Size Forecast (2018-2023)
    • 12.2 Global Oral Antidiabetic (OAD) Treatment Market Forecast by Regions (2018-2023)
    • 12.3 North America Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2018-2023)
    • 12.4 Europe Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2018-2023)
    • 12.5 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2018-2023)
    • 12.6 South America Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2018-2023)
    • 12.7 Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2018-2023)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. Various treatment method are present in the market injection, oral and others. The mostly used method of treatment or managing the diabetes is the oral.

      Scope of the Report:

      This report studies the Oral Antidiabetic (OAD) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Oral Antidiabetic (OAD) Treatment market by product type and applications/end industries.

      North America has the 44.3 million population with diabetes in 2015 according to the IDF, same as Europe have 59.8 million in 2015 according to IDF and Asia Pacific has 60% diabetic population as compared with world according to Asian Diabetes Prevention Initiative.

      The global Oral Antidiabetic (OAD) Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Oral Antidiabetic (OAD) Treatment.

      Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

      Market Segment by Companies, this report covers

      Pfizer

      Eli Lilly

      Merck

      Sanofi

      AstraZeneca

      Glenmark

      Novartis

      Boehringer Ingelheim

      Novo Nordisk

      Mannkind

      Market Segment by Regions, regional analysis covers

      North America (United States, Canada and Mexico)

      Europe (Germany, France, UK, Russia and Italy)

      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

      South America (Brazil, Argentina, Colombia)

      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers

      Sulphonylureas

      Biguanides

      Intestinal α-Glucosidase Inhibitors

      Others

      Market Segment by Applications, can be divided into

      Hospital

      Clinics

      Diabetics Treatment Centres

      Others




      Summary:
      Get latest Market Research Reports on Oral Antidiabetic (OAD) Treatment . Industry analysis & Market Report on Oral Antidiabetic (OAD) Treatment is a syndicated market report, published as Global Oral Antidiabetic (OAD) Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Oral Antidiabetic (OAD) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,480.00
      $5,220.00
      $6,960.00
      2,336.82
      3,505.23
      4,673.64
      3,202.30
      4,803.44
      6,404.59
      421,567.20
      632,350.80
      843,134.40
      230,770.63
      346,155.95
      461,541.26
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report